Lv21
130 积分 2023-11-25 加入
Ferroptosis in T cells: mechanisms, biology and translational opportunities
2天前
已完结
Efficacy and safety profile of busulfan plus low-dose melphalan (BUMEL) versus high-dose melphalan (MEL200) as a conditioning regimen for autologous hematopoietic stem cell transplantation (auto-HSCT) in multiple myeloma patients: a systematic review and meta-analysis
14天前
已完结
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
15天前
已完结
Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma
17天前
已完结
Cost-utility of pre-emptive plerixafor versus rescue plerixafor in the mobilization of hematopoietic stem cells in multiple myeloma
18天前
已完结
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
19天前
已完结
Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma
26天前
已完结
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
26天前
已完结